Fact CheckerSign in

NCT07404423Not yet recruiting

OPEN-IPF: Observational Prediction modEl for cliNical Outcomes in Idiopathic Pulmonary Fibrosis

Observational Prediction Model for Clinical Outcomes in Idiopathic Pulmonary Fibrosis: a Multicentre, ML-driven Study (OPEN-IPF)

Source: ClinicalTrials.gov · Last updated 11 Feb 2026

Brief summary (registry, in English)

Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with marked inter-individual heterogeneity in trajectories and outcomes. Despite antifibrotic therapies, reliable risk stratification in routine practice remains suboptimal. OPEN-IPF is a multicentre retrospective observational cohort study designed to build a harmonised real-world dataset across Italian IPF referral centres to enable the development and external validation of machine-learning (ML) models predicting clinically relevant outcomes.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
4 Feb 2026
Start date
1 Jun 2026
Primary completion date
1 Jan 2027
Lead sponsor
University of Modena and Reggio Emilia
NCT number
NCT07404423

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From 1 Jun 2026 to the primary completion date, 1 Jan 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Lung transplantation performed before the baseline (index) date

Other illness

  • Interstitial lung disease other than IPF

Other

  • Absence of any follow-up information after baseline

Who the study is looking for

  • Age ≥18 years
  • Diagnosis of idiopathic pulmonary fibrosis established according to international guidelines and local multidisciplinary team (MDT) assessment
  • Availability of baseline clinical and functional data
  • Availability of follow-up data for at least 12 months, or until a clinically relevant event (e.g., death, lung transplantation)

Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.